Group 1 - The core viewpoint of the articles is that the next-generation "in vivo CAR-T" technology is rapidly emerging, potentially addressing the high costs and accessibility issues associated with traditional CAR-T therapies [1][2]. - Traditional CAR-T therapy involves extracting a patient's T cells, modifying them in a lab, and reinfusing them, which is time-consuming and expensive, often exceeding 1 million yuan per treatment [1]. - In vivo CAR-T technology allows for direct modification of T cells within the patient's body using carriers like viruses or lipid nanoparticles, significantly simplifying the process and reducing costs [2]. Group 2 - The cost of in vivo CAR-T therapy is expected to drop to one-tenth of traditional methods, greatly enhancing accessibility for patients [2]. - The treatment process for in vivo CAR-T can yield results in as little as three days with just one or two intravenous injections, compared to the weeks required for traditional CAR-T [2]. - As the technology matures, patients may receive effective and durable cell therapies through simple injections, potentially expanding the range of treatable diseases and lowering overall medical costs [3].
120万天价治疗费有解?体内CAR-T有望降本至1/10
Di Yi Cai Jing·2025-09-22 12:09